• Innovative Eye Science

    Your vision is our focus

    Select Video
  • Play
    Select Video

At Inotek, we're working to define the future of glaucoma treatment.

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye.

Use the links above to view videos of our key leaders and contributors discussing Inotek's mission, vision, and the potential therapeutic value of our lead product candidate, trabodenoson.

A New Class of Glaucoma Therapy

Our most advanced product candidate, trabodenoson, is a highly selective adenosine mimetic and the first potential treatment for glaucoma of its kind.

Adenosine is an important molecule occurring naturally in the body that participates in a wide variety of physiological and pathological processes. Inotek’s scientists have deconstructed adenosine’s complex biology to isolate the protective activity of the molecule, and subsequently to build it into novel therapeutics.

Read More >


Inotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage Gene Therapy Company, Rocket Pharmaceuticals

- First Clinical Program in Fanconi Anemia Demonstrating Early Hematological Stabilization in Patients - - Additional First-in-human Results from up to Three Programs Expected in 2018 - LEXINGTON, Mass. & NEW YORK, NY--(BUSINESS WIRE)--Oct. 12, 2017-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) today announced the filing with the US Securities and Exchange Commission...

Read More >